

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



UNISOUND AI TECHNOLOGY CO., LTD.

雲知聲智能科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9678)

VOLUNTARY ANNOUNCEMENT LATEST TECHNOLOGICAL DEVELOPMENTS

This announcement is made by Unisound AI Technology Co., Ltd. (the “**Company**”) on a voluntary basis to inform the shareholders and potential investors of the Company of its latest technological developments.

Recently, the Company released its expert large model for the medical sector, “UniGpt Medical Large Model 5.0” (the “**Medical Large Model**”), establishing a dual-core product architecture comprising a “medical text large model + medical multimodal large model.” By covering core capabilities such as text processing, agent coordination, and multimodal perception, and integrating functions such as medical Q&A, clinical task planning and image analysis, it has become one of the most comprehensive medical AI technology support frameworks in the industry. The Medical Large Model is capable of deeply simulating clinical reasoning to perform complex inference, enabling precise differential diagnosis and evidence-based decision-making. Leveraging training on massive volumes of high-quality medical data and proprietary knowledge bases, the Company’s model has achieved industry-leading performance in core tasks such as medical knowledge Q&A and information extraction. Through continuous curriculum learning, knowledge graph augmentation, and evidence-based alignment training, it has minimized medical hallucinations, ensuring the authenticity and verifiability of generated outputs.

In December 2025, in MedBench 4.0, an authoritative domestic evaluation framework for Chinese medical large models developed by the Shanghai Artificial Intelligence Research Institute, the Company achieved outstanding scores of 94.6, 65.7, and 59.6 in the categories of medical agents, large language models, and multimodal large models, respectively, taking first place in all three technical paradigms of medical large models, setting a benchmark for the industry. Furthermore, in the MedAIBench Evaluation Ranking (Outstanding Domestic Medical Large Models) published by the National Artificial Intelligence Application Pilot Base (Medical), Zhejiang, the Company’s Medical Large Model was honored to be included on the list by virtue of its solid technical foundation, demonstrating robust capabilities in the AI healthcare vertical.

The Company's Medical Large Model has successfully achieved large-scale deployment and application across many Class-III Grade-A hospitals, and has completed technical validation in collaboration with these Class-III Grade-A hospitals in scenarios demanding high professional expertise, such as clinical diagnostic assistance. With technical capabilities deeply aligned with medical industry standards and real-world clinical requirements, the model fully demonstrates its clinical practical value and industry adaptability.

By Order of the Board
Unisound AI Technology Co., Ltd.
Dr. Huang Wei
Executive Director and General Manager

Beijing, the PRC
December 22, 2025

As of the date of this announcement, the board of directors of the Company comprises: (i) Dr. Liang Jia'en, Dr. Huang Wei, Dr. Kang Heng, Dr. Li Xiaohan and Dr. Liu Shengping as executive directors; (ii) Mr. Li Zhichao and Mr. Li Ang as non-executive directors; and (iii) Mr. Hu Jianjun, Dr. Fan Jian, Dr. Jin Huihua and Dr. Zhang Kun as independent non-executive directors.